[go: up one dir, main page]

CY1105446T1 - Διαγνωση και θepαπεια διαταραχων που συνδεονται με aur1 και aur2 - Google Patents

Διαγνωση και θepαπεια διαταραχων που συνδεονται με aur1 και aur2

Info

Publication number
CY1105446T1
CY1105446T1 CY20051101394T CY051101394T CY1105446T1 CY 1105446 T1 CY1105446 T1 CY 1105446T1 CY 20051101394 T CY20051101394 T CY 20051101394T CY 051101394 T CY051101394 T CY 051101394T CY 1105446 T1 CY1105446 T1 CY 1105446T1
Authority
CY
Cyprus
Prior art keywords
aur1
aur2
polypeptides
diagnosis
treatment
Prior art date
Application number
CY20051101394T
Other languages
English (en)
Inventor
Gregory D. Plowman
Kevin Mossie
Original Assignee
Sugen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen, Inc. filed Critical Sugen, Inc.
Publication of CY1105446T1 publication Critical patent/CY1105446T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με πολυπεπτίδια AUR1 και/ή AUR2, νουκλεϊκά οξέα που κωδικοποιούν αυτά τα πολυπεπτίδια, κύτταρα, ιστούς και ζώα που περιέχουν αυτά τα νουκλεϊκά οξέα, αντισώματα εναντίον αυτών των πολυπεπτιδίων, προσδιορισμούς που χρησιμοποιούν αυτά τα πολυπεπτίδια, και μεθόδους που σχετίζονται με όλα τα προαναφερόμενα. Παρέχονται μέθοδοι για θεραπεία, διάγνωση, και ανίχνευση ασθενειών ή παθήσεων που συνδέονται με AUR1 και/ή AUR2 που χαρακτηρίζονται από ανώμαλη αλληλεπίδραση μεταξύ πολυπεπτιδίου AUR1 και/ή AUR2 και εταίρου δέσμευσης AUR1 και/ή AUR2.
CY20051101394T 1998-01-22 2005-11-15 Διαγνωση και θepαπεια διαταραχων που συνδεονται με aur1 και aur2 CY1105446T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/012,135 US6716575B2 (en) 1995-12-18 1998-01-22 Diagnosis and treatment of AUR1 and/or AUR2 related disorders
PCT/US1999/001283 WO1999037788A2 (en) 1998-01-22 1999-01-21 Diagnosis and treatment of aur1 and/or aur2 related disorders

Publications (1)

Publication Number Publication Date
CY1105446T1 true CY1105446T1 (el) 2010-04-28

Family

ID=21753554

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20051101394T CY1105446T1 (el) 1998-01-22 2005-11-15 Διαγνωση και θepαπεια διαταραχων που συνδεονται με aur1 και aur2

Country Status (11)

Country Link
US (3) US6716575B2 (el)
EP (1) EP1051500B1 (el)
JP (1) JP2002508937A (el)
AT (1) ATE302278T1 (el)
AU (1) AU2560599A (el)
CA (1) CA2318352A1 (el)
CY (1) CY1105446T1 (el)
DE (1) DE69926731T2 (el)
DK (1) DK1051500T3 (el)
ES (1) ES2247783T3 (el)
WO (1) WO1999037788A2 (el)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL339005A1 (en) 1997-08-27 2000-12-04 Pioneer Hi Bred Int Genes encoding enzymes of lignin synthesis track and their applications
JP4590107B2 (ja) 1999-04-09 2010-12-01 中外製薬株式会社 新規胎児性遺伝子
EE200200715A (et) * 2000-06-28 2004-08-16 Astrazeneca Ab Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
KR100896664B1 (ko) * 2000-09-15 2009-05-14 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물
ATE326462T1 (de) 2000-12-21 2006-06-15 Vertex Pharma Pyrazolverbindungen als protein-kinase- inhibitoren
JP2002236125A (ja) * 2001-02-06 2002-08-23 Igaku Seibutsugaku Kenkyusho:Kk タンパク質リン酸化酵素活性の測定方法、測定用キット及び測定に用いる抗体
WO2002062989A2 (en) * 2001-02-08 2002-08-15 Sequitur, Inc. Methods of light activated release 0f ligands from endosomes
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
DE60329277D1 (de) 2002-02-01 2009-10-29 Life Technologies Corp Oligonukleotidzusammensetzungen mit verbesserter effizienz
EP1472245A2 (en) * 2002-02-06 2004-11-03 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
EP1485380B1 (en) * 2002-03-15 2010-05-19 Vertex Pharmaceuticals Incorporated Azolylaminoazines as inhibitors of protein kinases
EP1492871A2 (en) * 2002-03-28 2005-01-05 QLT Inc. Cancer associated protein kinases and their uses
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CA2494100C (en) 2002-08-02 2011-10-11 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
WO2004024063A2 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US7977471B2 (en) * 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US20100113307A1 (en) * 2002-11-14 2010-05-06 Dharmacon, Inc. siRNA targeting vascular endothelial growth factor (VEGF)
US20090227780A1 (en) * 2002-11-14 2009-09-10 Dharmacon, Inc. siRNA targeting connexin 43
US7635770B2 (en) * 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
US7781575B2 (en) 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
EP2284266B1 (en) * 2002-11-14 2013-11-06 Thermo Fisher Scientific Biosciences Inc. siRNA targeting tp53
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
US20080268457A1 (en) * 2002-11-14 2008-10-30 Dharmacon, Inc. siRNA targeting forkhead box P3 (FOXP3)
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US7592442B2 (en) * 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7619081B2 (en) * 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US7691998B2 (en) * 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
AU2003295598B2 (en) * 2002-11-15 2009-12-24 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
DK1847539T3 (da) 2002-12-24 2009-11-09 Astrazeneca Ab Quinazolin-derivater
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004072029A2 (en) * 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
JP2006521793A (ja) * 2003-02-06 2006-09-28 ゲノミック ヘルス， インコーポレイテッド Ｅｇｆｒインヒビター薬物に応答性の遺伝子発現マーカー
DE602004017426D1 (de) * 2003-02-20 2008-12-11 Genomic Health Inc Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression
US20050164218A1 (en) * 2003-05-30 2005-07-28 David Agus Gene expression markers for response to EGFR inhibitor drugs
CA3061769C (en) * 2003-06-24 2021-10-26 Genomic Health, Inc. Methods of predicting the likelihood of long-term survival of a human patient with node-negative, estrogen receptor (er) positive, invasive ductal breast cancer without the recurrence of breast cancer
ES2905579T3 (es) 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
JP2007509613A (ja) * 2003-10-16 2007-04-19 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現プロファイリングのためのｑＲＴ−ＰＣＲアッセイシステム
US7592340B2 (en) * 2003-12-04 2009-09-22 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
ATE498022T1 (de) * 2003-12-23 2011-02-15 Genomic Health Inc Universelle vervielfältigung von fragmentierter rns
CA2848463A1 (en) * 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2005106044A1 (en) * 2004-04-23 2005-11-10 Exagen Diagnostics, Inc. Compositions and methods for breast cancer prognosis
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
US7605250B2 (en) * 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
EP1763514A2 (en) * 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20050282208A1 (en) * 2004-06-18 2005-12-22 Cytokinetics, Inc. Cellular phenotype
WO2006023931A2 (en) * 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7491720B2 (en) * 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
NZ554441A (en) * 2004-10-29 2009-07-31 Banyu Pharma Co Ltd Novel aminopyridine derivatives having aurora A selective inhibitory action
EP1815014B1 (en) * 2004-11-05 2012-03-21 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
EP1836629B1 (en) 2004-11-05 2020-03-04 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
GB2420559B (en) * 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
BRPI0517737A (pt) 2004-11-17 2008-10-21 Miikana Therapeutics Inc inibidores de quinase
US20060142247A1 (en) * 2004-12-17 2006-06-29 Guy Georges Tricyclic heterocycles
WO2006108488A1 (en) * 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
AU2006233537A1 (en) 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
EP1860438B1 (en) * 2005-08-12 2009-11-18 Astellas Pharma Inc. Method for identifying target protein of agent and method for screening therapeutic agent for diabetes using target protein
ATE542814T1 (de) * 2005-08-18 2012-02-15 Vertex Pharma Pyrazinkinaseinhibitoren
WO2007030795A2 (en) * 2005-09-09 2007-03-15 Cytokinetics, Inc. Cellular phenotype
NZ567241A (en) * 2005-09-30 2010-08-27 Miikana Therapeutics Inc Substituted pyrazole compounds
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP5328361B2 (ja) * 2005-11-03 2013-10-30 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリミジン
AU2007229063A1 (en) * 2006-03-20 2007-09-27 F. Hoffmann-La Roche Ag Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents
EP2001882A1 (en) * 2006-03-23 2008-12-17 F. Hoffmann-La Roche AG Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
MX2009003793A (es) 2006-10-09 2009-12-14 Takeda Pharmaceutical Inhibidores de cinasa.
EP2086965B1 (en) * 2006-11-02 2010-02-10 Vertex Pharmaceuticals, Inc. Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
EP2099787B1 (en) * 2006-12-19 2010-07-21 Vertex Pharmaceuticals, Inc. Aminopyrimidines useful as inhibitors of protein kinases
CN101663295B (zh) * 2007-03-09 2014-11-05 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的氨基嘧啶类化合物
NZ579483A (en) 2007-03-09 2012-07-27 Vertex Pharma Aminopyridines useful as inhibitors of protein kinases
CN101668760B (zh) * 2007-03-09 2013-07-24 沃泰克斯药物股份有限公司 用作蛋白激酶抑制剂的氨基嘧啶类
NZ580343A (en) 2007-04-13 2012-03-30 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
CN101801959A (zh) * 2007-05-02 2010-08-11 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶类化合物
WO2008137619A2 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
JP5572087B2 (ja) * 2007-05-02 2014-08-13 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害として有用なアミノピリミジン
CA2687966A1 (en) * 2007-05-24 2008-12-04 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
EP2166849A4 (en) * 2007-06-11 2010-09-15 Miikana Therapeutics Inc SUBSTITUTED PYRAZOL COMPOUNDS
CA2694499A1 (en) * 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
RU2011112802A (ru) * 2008-09-03 2012-10-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Сокристаллы и содержащие их фармацевтические композиции
US9799416B2 (en) * 2009-11-06 2017-10-24 Terrapower, Llc Methods and systems for migrating fuel assemblies in a nuclear fission reactor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343940A (en) 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
EP0031237B1 (en) 1979-12-19 1984-10-17 National Research Development Corporation Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
DE3611194A1 (de) 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3920029C2 (de) 1988-06-30 1999-05-20 Clariant Finance Bvi Ltd Farbstoffe zum Färben von Kunststoffen
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
CA2078214C (en) 1990-04-02 1995-03-28 Robert Lee Dow Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
DK0536350T3 (da) * 1991-02-22 2002-09-02 American Cyanamid Co Identifikation af et nyt humant receptor-tyrosinkinase-gen
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0586608A1 (en) 1991-05-29 1994-03-16 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9205320D0 (en) 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
SK283413B6 (sk) 1992-08-06 2003-07-01 Warner-Lambert Company 2-Tioindoly, 2-indolíntióny a polysulfidy, ich selénové analógy a farmaceutické prostriedky na ich báze
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
EP0703984A1 (en) 1993-04-07 1996-04-03 Cancer Research Campaign Technology Limited Methods for screening of substances for therapeutic activity and yeast for use therein
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5830648A (en) 1995-05-05 1998-11-03 Sugen, Inc. Assay and method for transcript imaging
DE69635740T2 (de) 1995-12-18 2006-09-14 Sugen, Inc., South San Francisco Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen

Also Published As

Publication number Publication date
WO1999037788A9 (en) 1999-11-04
CA2318352A1 (en) 1999-07-29
US20020081578A1 (en) 2002-06-27
JP2002508937A (ja) 2002-03-26
DE69926731T2 (de) 2006-05-18
ES2247783T3 (es) 2006-03-01
WO1999037788A2 (en) 1999-07-29
ATE302278T1 (de) 2005-09-15
US6841579B1 (en) 2005-01-11
US6716575B2 (en) 2004-04-06
AU2560599A (en) 1999-08-09
US6207401B1 (en) 2001-03-27
WO1999037788A3 (en) 1999-09-30
DE69926731D1 (de) 2005-09-22
EP1051500A2 (en) 2000-11-15
EP1051500B1 (en) 2005-08-17
DK1051500T3 (da) 2005-12-19
US20050002938A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
CY1105446T1 (el) Διαγνωση και θepαπεια διαταραχων που συνδεονται με aur1 και aur2
PT868519E (pt) Diagnostico e tratamento de disturbios relacionados com aur-1 e/ou aur-2
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
ATE182180T1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
DE69837529D1 (de) Proteinmarker für lungenkrebs und deren verwendung
PT991421E (pt) Deteccao e modulacao das iap e naip para o diagnostico e tratamento de doenca proliferativa
CY1112330T1 (el) Πρωτεϊνες συνδεσης gag
ATE364696T1 (de) Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
DE59903915D1 (de) Verfahren zur frühen diagnose von carcinomen
EA200101037A1 (ru) Соединения и способы для лечения и диагностики рака легкого
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
DE69938662D1 (de) Spurendetektion von analyten mit hilfe artifizieller olfaktometrie
DE69833014D1 (de) Menschliche toll homologen
DE69735436D1 (de) Methode zum nachweis von zell-apoptose
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
ATE265533T1 (de) Saeugetierchemokine
MXPA02000293A (es) Isoformas de la amp ciclico fosfodiesterasa y metodos de uso.
DE69939379D1 (de) Hemmstoff zur diagnose und behandlung von haemophilia a patienten
DE69734890D1 (de) Rdgb-proteine
DE50015355D1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
NO930406L (no) Spesifikke antistoffer mot aktiverte blodplater samt fremstilling derav
DE69939583D1 (de) Chondrosarcom-assoziierte gene